Connexin (Gap Junction Protein) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Connexin (Gap Junction Protein) - Pipeline Review, H1 2016', provides in depth analysis on Connexin (Gap Junction Protein) targeted pipeline therapeutics. The report provides comprehensive information on the Connexin (Gap Junction Protein) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Connexin (Gap Junction Protein) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Connexin (Gap Junction Protein) - The report reviews Connexin (Gap Junction Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Connexin (Gap Junction Protein) targeted therapeutics and enlists all their major and minor projects - The report assesses Connexin (Gap Junction Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Connexin (Gap Junction Protein) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Connexin (Gap Junction Protein) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Connexin (Gap Junction Protein) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Connexin (Gap Junction Protein) Overview 6 Therapeutics Development 7 Connexin (Gap Junction Protein) - Products under Development by Stage of Development 7 Connexin (Gap Junction Protein) - Products under Development by Therapy Area 8 Connexin (Gap Junction Protein) - Products under Development by Indication 9 Connexin (Gap Junction Protein) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Connexin (Gap Junction Protein) - Products under Development by Companies 12 Connexin (Gap Junction Protein) - Products under Development by Universities/Institutes 14 Connexin (Gap Junction Protein) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 19 Assessment by Molecule Type 20 Connexin (Gap Junction Protein) - Companies Involved in Therapeutics Development 22 Theranexus SAS 22 Vichem Chemie Research Ltd. 23 Connexin (Gap Junction Protein) - Drug Profiles 24 (flecainide acetate + modafinil) - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 CODA-001 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Synthetic Peptide to Inhibit Connexin for Optic Neuropathy - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 THN-01 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 VID-45110 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Connexin (Gap Junction Protein) - Dormant Projects 31 Connexin (Gap Junction Protein) - Discontinued Products 33 Connexin (Gap Junction Protein) - Featured News & Press Releases 34 May 17, 2016: Theranexus Reaches Its Primary Endpoint in the Proof of Concept Trial of THN102 in Excessive Daytime Sleepiness 34 Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep 35 Jul 15, 2015: Theranexus Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies 35 Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers 36 May 25, 2010: CoDa Therapeutics Achieves Positive Results From Phase II Efficacy Study Of NEXAGON In Chronic Venous Leg Ulcers 37 May 11, 2009: CoDa Therapeutics Receives Orphan Drug Designation For Nexagon For The Treatment Of Persistent Corneal Epithelial Defects 37 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 18 Number of Products by Stage and Route of Administration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 21 Pipeline by Theranexus SAS, H1 2016 22 Pipeline by Vichem Chemie Research Ltd., H1 2016 23 Dormant Projects, H1 2016 31 Dormant Projects (Contd..1), H1 2016 32 Discontinued Products, H1 2016 33
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.